Feature | September 14, 2012

SCAI Launches Cath Lab AUC and Guidelines App

AUC calculator app is latest addition to SCAI Quality Improvement Toolkit

September 14, 2012 — Coronary revascularization appropriate use criteria (AUC) are now just a click away with the new SCAI Quality Improvement Toolkit (SCAI-QIT) AUC and Guidelines App, launched this week by the Society for Cardiovascular Angiography and Interventions (SCAI).

“The new app is a calculator tool that makes it simple to access the AUC on heart revascularization without having to carry around printed documents,” said Kalon Ho, M.D., FSCAI, architect of the new tool. “While we don’t intend for this tool to replace clinical judgment, we do hope it provides easier access to information that can guide the cath lab team’s decisions.”

Once members of the cardiac catheterization lab team input facts about a patient’s case, the app will indicate where a “typical” case with those same characteristics would fall on a spectrum of “appropriate,” “uncertain” or “inappropriate” for revascularization, as defined by the latest recommendations from leading cardiology societies, including SCAI and the American College of Cardiology Foundation, among others. Interventional cardiologists can then use that information to make recommendations for treatment of individual patients’ symptoms and conditions. 

SCAI’s calculator app also recognizes that complete documentation is essential in today’s healthcare environment. The app providers users with key data, including the relevant AUC scenario number, the indication score, a summary of the patient’s case and a link to a printer-friendly reporting sheet that can be added to the patient’s chart.  

In coming months, SCAI will expand the app with new modules to help healthcare providers access interventional cardiology guidelines and additional AUC, including those for diagnostic cardiac catheterization. Plans are also underway for the app to include options for interfacing with electronic health records (EHR), further assisting providers with documentation.

The AUC and Guidelines App is part of the expanded SCAI-QIT developed by SCAI’s Quality Improvement Committee to provide tools and resources that help both facilities and providers deliver consistent quality care to cath lab patients. Currently tools focus on guidelines and AUC, national database participation, inventory management, pre-procedure activities, operator and staff requirements, procedural quality and best practices, as well as facility and environmental issues. Each tool is regularly updated to incorporate the latest guidelines, regulatory requirements and feedback from the many SCAI Quality Champions who are using the tools in cath labs around the world.

“The SCAI-QIT has become an important resource for continuously improving cath lab quality. Within months of its launch, interventional cardiologists began telling us how SCAI-QIT helps them identify and address opportunities for improvement,” said SCAI Immediate Past President Christopher J. White, M.D., FSCAI. “The new AUC Calculator App is an example of a tool that will help cath lab teams easily access information supportive of high-quality, evidence-based patient care.”

The SCAI-QIT was developed with founding support from Daiichi Sankyo Lilly and support from AstraZeneca.

For more information: www.SCAI-QIT.org

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major